# Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

> **NCT00800007** · PHASE1,PHASE2 · TERMINATED · sponsor: **Anza Therapeutics, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** ANZ-521
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00800007
- **Lead sponsor:** Anza Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2009-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00800007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00800007, "Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00800007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*